Topic Archives: Forecasts & strategies

Today we take a gander at a pitch from Mark Skousen, who has been a newsletter guy for decades with his Forecasts & Strategies newsletter (he’s also an itinerant economics professor, and runs the big “freedomfest” conference in Las Vegas each year, among other things). And the headline of his latest “presentation” pretty well sums […]

Today I decided to sit down for a while with a teaser ad from Dr. Mark Skousen’s Forecasts & Strategies ($50/year) — this letter is actually from his publisher, Roger Michalski, but it focuses on an idea of Skousen’s that he calls “American X”. So what is this secret “American X” company? It’s apparently got […]

This is a combo you don’t hear about very often, “founded in the 17th century” and “cancer killing blockbuster” … usually, the little biotechs that newsletters drop hints about are tiny, young, risky, sometimes fly-by-night outfits that are betting it all on a clinical breakthrough. Not this time, apparently. So that’s why my eye was […]

Retirees and those who are near retirement are desperate for income — bond yields are ridiculously low, not just for municipal bonds and Treasuries but for riskier corporate bonds, CD rates are too low to take seriously, even dividends are getting lower as more and more investors overpay for income… so the marketplace is ripe […]

Today’s teasers come in from Mark Skousen, who edits the Forecasts & Strategies newsletter and has graced our pages a few times in the past — most recently when he touted Cubist Pharmaceuticals very aggressively as a “winning lottery ticket” and “superbug killer” (that one did quite well, thanks to both the FDA and a […]

Mark Skousen, who is one of those Ph.D-type doctors (economics) and thankfully doesn’t always insist on being called Dr. Skousen (yes, we’re looking at you Dr. Leeb), is pitching a health care stock today as a teaser for his Forecasts and Strategies newsletter. And like some folks we’ve heard from in the past, he’s teasing […]

Many of you saw this email last week, the latest in a long string of Mark Skousen’s attempts to predict breakout stock performance on earnings dates. His past history of this is spotty, and I’ve written a few times about earnings pops he has predicted — some good, some bad. Alas, I didn’t get a […]

Comments

  • Avatar

    This is one of those newsletters that's advertised as $5,000 a year but is always on sales. (Same for Katusa and others...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch